Insulin: discovery and controversy
- PMID: 12446492
Insulin: discovery and controversy
Abstract
During the first two decades of the 20th century, several investigators prepared extracts of pancreas that were often successful in lowering blood sugar and reducing glycosuria in test animals. However, they were unable to remove impurities, and toxic reactions prevented its use in humans with diabetes. In the spring of 1921, Frederick G. Banting, a young Ontario orthopedic surgeon, was given laboratory space by J.J.R. Macleod, the head of physiology at the University of Toronto, to investigate the function of the pancreatic islets. A student assistant, Charles Best, and an allotment of dogs were provided to test Banting's hypothesis that ligation of the pancreatic ducts before extraction of the pancreas, destroys the enzyme-secreting parts, whereas the islets of Langerhans, which were believed to produce an internal secretion regulating sugar metabolism, remained intact. He believed that earlier failures were attributable to the destructive action of trypsin. The name "insuline" had been introduced in 1909 for this hypothetic substance. Their experiments produced an extract of pancreas that reduced the hyperglycemia and glycosuria in dogs made diabetic by the removal of their pancreases. They next developed a procedure for extraction from the entire pancreas without the need for duct ligation. This extract, now made from whole beef pancreas, was successful for treating humans with diabetes. Facilitating their success was a development in clinical chemistry that allowed blood sugar to be frequently and accurately determined in small volumes of blood. Success with purification was largely the work of J.B. Collip. Yield and standardization were improved by cooperation with Eli Lilly and Company. When the Nobel Prize was awarded to Banting and Macleod for the discovery of insulin, it aggravated the contentious relationship that had developed between them during the course of the investigation. Banting was outraged that Macleod and not Best had been selected, and he briefly threatened to refuse the award. He immediately announced that he was giving one-half of his share of the prize money to Best and publicly acknowledged Best's contribution to the discovery of insulin. Macleod followed suit and gave one-half of his money award to Collip. Years later, the official history of the Nobel Committee admitted that Best should have been awarded a share of the prize.
Similar articles
-
[The discovery of insulin: what really happened 80 years ago].Ann Ital Med Int. 2001 Jul-Sep;16(3):155-62. Ann Ital Med Int. 2001. PMID: 11692904 Italian.
-
Insulin's centenary: the birth of an idea.Lancet Diabetes Endocrinol. 2020 Dec;8(12):971-977. doi: 10.1016/S2213-8587(20)30337-5. Epub 2020 Oct 29. Lancet Diabetes Endocrinol. 2020. PMID: 33129375 Review.
-
Sir Frederick Grant Banting - the discoverer of insulin. On the 100th anniversary on the Nobel Prize.Przegl Epidemiol. 2023;77(1):108-118. doi: 10.32394/pe.77.11. Przegl Epidemiol. 2023. PMID: 37283324
-
La découverte de l’insuline 1921–1922 : un saut dans la recherche biomédicale.Biol Aujourdhui. 2022;216(1-2):1-6. doi: 10.1051/jbio/2022006. Epub 2022 Jul 25. Biol Aujourdhui. 2022. PMID: 35876516 French.
-
Insulin Therapy: The Discovery That Shaped a Century.Can J Diabetes. 2021 Dec;45(8):798-803. doi: 10.1016/j.jcjd.2021.03.002. Epub 2021 Mar 25. Can J Diabetes. 2021. PMID: 34045148 Review.
Cited by
-
TED: Enhancing Translation Efficiency in Bacterial Expression Systems.Methods Mol Biol. 2024;2844:211-218. doi: 10.1007/978-1-0716-4063-0_14. Methods Mol Biol. 2024. PMID: 39068342
-
Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms.Biomolecules. 2024 Feb 22;14(3):264. doi: 10.3390/biom14030264. Biomolecules. 2024. PMID: 38540684 Free PMC article. Review.
-
Computational Approach to Elucidating Insulin-Protamine Binding Interactions and Dynamics in Insulin NPH Formulations.ACS Omega. 2024 Jan 18;9(4):4857-4869. doi: 10.1021/acsomega.3c08445. eCollection 2024 Jan 30. ACS Omega. 2024. PMID: 38313521 Free PMC article.
-
Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment.Ther Adv Endocrinol Metab. 2023 Jun 29;14:20420188231180987. doi: 10.1177/20420188231180987. eCollection 2023. Ther Adv Endocrinol Metab. 2023. PMID: 37440840 Free PMC article.
-
Insulin dependent diabetes and anthropometric assessment: Understanding the rationale for body composition measurement.Afr J Diabetes Med. 2022 Jun;30(6):30-6-1. doi: 10.54931/2053-4787.30-6-1. Afr J Diabetes Med. 2022. PMID: 37255736 Free PMC article.
Publication types
MeSH terms
Substances
Personal name as subject
- Actions
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical